This is a registry record, not a result. A trial being listed, recruiting or completed says nothing by itself about whether the compound works or is safe.
| Registry number | NCT07220759 |
|---|---|
| Status | Active not recruiting |
| Phase | Phase 3 |
| Sponsor | Novo Nordisk A/S |
| Enrollment | 330 participants |
| Design | Interventional, Randomized, Parallel, Masking: Quadruple |
| Conditions | Overweight; Obesity; Type 2 Diabetes |
| Interventions | Cagrilintide; Placebo (matched to Cagrilintide) |
| Start | Nov 5, 2025 |
| Primary completion | May 12, 2027 |
| Study completion | Jun 30, 2027 |
| Results posted | Not yet |
| Registry last updated | Sep 4, 2026 |
Compounds on this site that cite this trial
What the registry says the trial is about
This study will look at how much cagrilintide helps people with overweight or obesity and type 2 diabetes lower their body weight. Cagrilintide is a new investigational medicine. Doctors may not yet prescribe cagrilintide. Participant will either get cagrilintide or placebo. Which treatment participant get is decided by chance. Participants are two times more likely to get cagrilintide than placebo. Like all medicines, the study medicine may have side effects. For each participant, the study will last for about 1 year and 6 months.
Primary outcomes
These are what the trial was designed to measure first. They are registered in advance, which is what makes a later result checkable.
| Outcome measure | Time frame |
|---|---|
| Relative change in body weight | From baseline (week 0) to end of treatment (week 64) |
28 secondary outcomes also registered. See the registry record for the full list.
Source: ClinicalTrials.gov (U.S. National Library of Medicine). Last checked against the registry on Oct 3, 2026. See the trial changes feed for what has changed recently.
